Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bicara Therapeutics Inc. - Common Stock (NQ:BCAX)

16.26 -1.99 (-10.90%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bicara Therapeutics Inc. - Common Stock

< Previous 1 2 Next >
These stocks that are showing activity before the opening bell on Monday.
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC
Designation supported by results from multiple dose cohorts from the Phase 1/1b trial of ficerafusp alfa in 1L HPV-negative R/M HNSCC 
From Bicara Therapeutics Inc.
Via GlobeNewswire
4 Biotech Stocks Seeing Explosive Momentum Gains
The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the biotech space that appear to be... 
Via Benzinga
Topics ETFs Stocks
Bicara Therapeutics to Participate in Upcoming Investor Conferences
From Bicara Therapeutics Inc.
Via GlobeNewswire
Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Bicara Therapeutics Inc.
Via GlobeNewswire
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
From Relay Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
From Bicara Therapeutics Inc.
Via GlobeNewswire
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025
From Bicara Therapeutics Inc.
Via GlobeNewswire
Bicara Therapeutics Shares Sink Over 43% On Mixed Phase 1/1b Trial Results: What's Going On?
Bicara Therapeutics Inc. (NASDAQ: BCAX) shares are trading lower Friday following the release of updated interim data. 
Via Benzinga
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Let's take a look at the stocks that are in motion in today's session.
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Gold Gains Over 1%; Ross Stores Shares Dip After Pulling Fiscal 2026 Outlook
 
Via Benzinga
There are notable gap-ups and gap-downs in today's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
Nasdaq Down Over 1%; Workday Shares Tumble After Q1 Results
 
Via Benzinga
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics
The companies are duking it out for the best treatment for head-and-neck cancer. One clearly has the edge. 
Via Investor's Business Daily
Ross Stores, Deckers Outdoor, Xerox Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
Discover the top movers in Friday's pre-market session.
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Pentair To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday
 
Via Benzinga
Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting
Company to host conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to discuss fulsome dataset 
From Bicara Therapeutics Inc.
Via GlobeNewswire
Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Bicara Therapeutics Inc.
Via GlobeNewswire
Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025
From Bicara Therapeutics Inc.
Via GlobeNewswire
Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
From Bicara Therapeutics Inc.
Via GlobeNewswire
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
 
Via Benzinga
Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Bicara Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
From Bicara Therapeutics Inc.
Via GlobeNewswire
Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
From Bicara Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.